MMP-9-IN-1 是一种特异性的基质金属蛋白酶-9 (MMP-9) 抑制剂，选择性靶向 MMP-9 的血红素 (PEX) 域，但不作用于其他 MMP。
| 生物活性 | MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which
selectively target the hemopexin (PEX) domain ofMMP-9, but not other MMPs[1]. |
| IC50& Target[1] | |
体外研究
(In Vitro) | MMP-9-IN-1 (compound 2; 100 μM; 14 hours) does not cause notable cytotoxicity[1].
MMP-9-IN-1 (compound 2; 10 μM) significantly inhibits cell proliferation of HT-1080 and MDA-MB-435 cells[1].
Cell Cytotoxicity Assay[1] | Cell Line: | COS-1 monkey epithelial cell lines | | Concentration: | 100 μM | | Incubation Time: | 24 hours | | Result: | Treatment did not cause notable cytotoxicity. |
Cell Proliferation Assay[1] | Cell Line: | HT-1080 and MDA-MB-435 cancer cells expressing endogenous MMP-9 | | Concentration: | 10 μM | | Incubation Time: | 9 days | | Result: | Significant inhibition of cell proliferation. |
|
体内研究
(In Vivo) | MMP-9-IN-1 (compound 2; 20 mg/kg; intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks) results in a profound delay in tumor growth in NCR-Nu mice bearing MDA-MB-435/GFP tumor[1].
MMP-9-IN-1 inhibits cancer cell metastasis in vivo[1].
| Animal Model: | 4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor[1] | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks, | | Result: | Resulted in a profound delay in tumor growth.
Inhibited cancer cell metastasis. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 125 mg/mL(338.40 mM;Need ultrasonic) 配制储备液 | 1 mM | 2.7072 mL | 13.5358 mL | 27.0717 mL | | 5 mM | 0.5414 mL | 2.7072 mL | 5.4143 mL | | 10 mM | 0.2707 mL | 1.3536 mL | 2.7072 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 50% PBS Solubility: 5 mg/mL (13.54 mM); Suspended solution; Need ultrasonic 2. 请依序添加每种溶剂： 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (5.63 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.63 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
*以上所有助溶剂都可在本网站选购。 |
